A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.9408 USD -2.58% Market Closed
Market Cap: 89.7m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Assertio Holdings Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Income from Continuing Operations
-$68.5m
CAGR 3-Years
-31%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$14.8B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$7.2B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$12.2B
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
89.7m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.5439 USD
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Income from Continuing Operations?
Income from Continuing Operations
-68.5m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Income from Continuing Operations amounts to -68.5m USD.

What is Assertio Holdings Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-7%

Over the last year, the Income from Continuing Operations growth was 63%. The average annual Income from Continuing Operations growth rates for Assertio Holdings Inc have been -31% over the past three years , -7% over the past five years .

Back to Top